390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors
Main Authors: | Thomas Davis, Jessica Price, Ammar Sukari, Roger Cohen, Przemyslaw Twardowski, Jessica Flechtner, Melissa Johnson, Maura Gillison, Rudy Lackner, Arthur DeCillis, Richard Hernandez, Kevin Mancini, Mara Shainheit |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
413 GEN-009, a personalized neoantigen vaccine, elicits robust immune responses in individuals with advanced or metastatic solid tumors
by: Thomas Davis, et al.
Published: (2020-11-01) -
m112b1f16_009
Published: () -
m94b1f33_009
Published: () -
m112b1f2_009
Published: () -
m94b3f16_009
Published: ()